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Transgenic Leishmania major and Leishmania donovani axenic promastigotes constitutively expressing mCherry were used for
in vitro antileishmanial drug screening. This method requires minimal sample manipulation and can be easily adapted to auto-
matic drug tests, allowing primary high-throughput screenings without the need for expensive and sophisticated instruments.
Protozoan parasites of the genus Leishmania are the causativeagents of a wide spectrum of human and animal diseases. The
clinical manifestations of Leishmania infections range from le-
sions of the skin and mucous membranes to lethality, the latter
caused by visceral species, including Leishmania donovani (1).
Leishmania species cause morbidity and mortality throughout
large areas of the Old and NewWorld. Leishmaniasis is an emerg-
ing disease with an annual incidence of 2 million cases, and more
than 12million people are infected in over 80 countries where the
disease is endemic (2), causing 80,000 deaths per year, and 350
million people are at risk of infection and disease. The increased
prevalence of Leishmania-human immunodeficiency virus (HIV)
coinfection is the major reason for the recent emergence of leish-
maniasis in the Western world (3).
Since their discovery in the 1940s, the highly toxic pentava-
lent antimonials [Sb(V)] have been the primary first-line treat-
ment for all types of leishmaniasis in most parts of the world.
However, the increasing frequency of relapse in leishmaniasis
patients is forcing the use of other chemotherapeutic agents,
including amphotericin B, isethionate pentamidine, paromo-
mycin, and miltefosine (4, 5). Unfortunately, the majority of
these antiparasitic drugs present severe side effects, there is no
guarantee of cure, and some of them are frequently accompa-
nied by emergence of drug resistance (6–8).
Alternative treatments are needed; however, advances in drug
discovery approaches have not been satisfactory. Although the use
of axenic promastigote cultures of Leishmania as a primary
screening method has being validated (7–11), the traditional ap-
proaches employed to determine the drug effect in culture present
several shortcomings. Microscopic counting is prone to error,
time-consuming, and requires trained personnel; the use of tetra-
zolium salts such as MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-di-
phenyl-2H-tetrazolium bromide] to measure cell viability is la-
bor-intensive, and results are not always reliable (12). The more
sensitive and less labor-intensive colorimetric resazurin-based
method may present variable metabolic behavior under different
cell culture conditions. Furthermore, it is not appropriate to per-
form kinetic experiments due to the significant cytotoxicity that
results from prolonged exposure to the reagent (13–15). Other
disadvantages of these metabolic assays are the requirement to
incubate the substrate with viable cells at 37°C for a sufficient time
to generate a measurable signal. This may lead to undesirable ar-
tifacts resulting from interactions between the reagent, the tested
drug, and the biochemistry of the cells (16). On the basis of these
considerations, there is a strong need to develop appropriate
screening technologies. The use of fluorescent reporter genes
such as those coding for green fluorescent protein (GFP) (17–
19) and the red versions red fluorescent protein (RFP) (20, 21)
and mCherry (21, 22) have considerably facilitated the screening
and testing of antimicrobial agents against axenic amastigotes and
intracellular amastigotes, allowing both in vitro and real-time
visualization in vivo. Although animal models are well established
for large-scale primary drug screening, its practical use is limited
due to high costs.
Here, we introduce a simple fluorometric method for primary
drug screening using red fluorescent promastigotes.We generated
Leishmaniamajor and L. donovani parasite cultures stably express-
ing themCherry gene, whose product is a redmonomeric fluores-
cent protein derived from the nowadays obsolete tetrameric Dis-
cosoma protein DsRED and presents an excitation maximum at
587 nm (587ex) and an emission maximum at 610 nm (610em).
mCherry is constitutively expressed in the cytoplasm, presents
high photostability, is resistant to photobleaching, and does not
require posttranslational modifications like GFP does. It matures
very rapidly, allowing fluorescence detection shortly after the gene
is expressed, which is appropriate for real-time analysis (12, 23).
L. major promastigotes (MHOM/JL/80/Friedlin) and L. don-
ovani promastigotes (MHOM/SD/62/1S-CL2D) weremaintained
at 27°C in M199 medium supplemented with 10% fetal bovine
serum (FBS; Atlanta Biolabs). The mCherry gene (711 bp) was
obtained from the pmCherry-N1 vector (Clontech, PaloAlto, CA)
by PCR amplification (LongAmp Taq; NEB). The PCR product
was purified and cloned into pGEMT (Promega) to create the
constructmCherry-pGEMT and further subcloned into the Leish-
mania expression vector pLEXSY-Hyg2 (Jena Bioscience) (Fig.
1A). Five micrograms of the resulting expression plasmid
mCherry-pLEXSY was digested with SwaI. The linearized expres-
sion cassette was electroporated as described previously into L.
major and L. donovani log-phase cultures, and transfected para-
sites were selected in the presence of hygromycin B (Sigma) at a
final concentration of 75 g/ml (24). Integration into the chro-
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mosomal 18S rRNA locus (ssu) was confirmed by PCR. A primer
pair including one primer hybridizing within the expression cas-
sette (P3) and another hybridizing to an ssu sequence not present
on the plasmid was used (Fig. 1A). Additional PCRs that involved
mCherry-specific primers (P2 and P3) were performed. A band of
1,279 kbp confirmed the integration of the gene, and a band of 711
bp was also obtained for mCherry-positive clones. Primer se-
quences are available upon request.
mCherry expression in the two Leishmania species was tested
by epifluorescence microscopy (Nikon 90/NikonAZ 100). Cells
were washed with phosphate-buffered saline (PBS), fixed in 4%
formaldehyde, and subsequently stained with NucBlue fixed cell
stain (Life Technologies) to visualize the nucleus and kinetoplast
(magnification,60). Transgenic parasites showed normal DNA
content and bright cytoplasmic red fluorescence, indicating that
the fixation step did not quench mCherry fluorescence, making
this cell line extremely valuable (Fig. 1B). The high level of fluo-
rescence detected was maintained in the axenic amastigote stage
(data not shown). mCherry expression was also analyzed in wild-
type (WT) and transgenic promastigotes in a Beckman Coulter
FC500 MPL flow cytometer (Fig. 1B). Morphometric profiles of
transfected parasites were comparable to the WT ones (data not
shown). To examine parasite fitness, the growth rate of transfected
cultures was measured and compared to that of WT strains. Par-
asites were seeded in triplicate (5 105 cells/ml), and the concen-
trations of L. major and L. donovani WT (LmWT and LdWT)
cultures and L. major and L. donovani mCherry-pLEXSY (Lm-
Cherry and LdCherry) cultures were assessed daily by direct mi-
croscopic counting until the parasites reached stationary phase.
No differences were observed in parasite growth rates (Fig. 1C).
Additionally, to evaluate culture fluorescence in relation to para-
site concentration, the fluorescence of each culture was measured
FIG 1 (A) Integration of the mCherry-pLEXSY expression cassette into the Leishmania 18S rRNA locus previously linearized with SwaI. The black arrow
indicates the start of transcription from the rRNA genes. Hygromycin B (hyg2) is used as a selectionmarker. P1 (blue arrow) and P2 and P3 (red arrows) indicate
the positions where primers anneal (upper panel). Diagnostic PCR was performed to corroborate genomic integration. A band of 711 bp was obtained from
mCherry-positive clones of L.major (lane 2) and L. donovani (lane 5). Integration ofmCherry-pLEXSY into the L.major and L. donovani genomicDNA appeared
as a 1.3-kbp fragment, not obtained fromWT strains (lanes 1 and 4). Lane MW, molecular size markers. (B) mCherry detection by epifluorescence microscopy
and flow cytometry analysis. Bright-field (a), NucBlue fixed cell stain (b), and red fluorescent (c) images of L. donovani expressingmCherry are shown. Scale bar,
10 m. (d) Histograms of fluorescence intensity of WT (dotted line) and transfected (red filled) L. donovani promastigotes. (C) Growth curves of WT and
transfected L. major and L. donovani parasites. (D) Quantification of mCherry fluorescence. The graph shows a linear relationship between the number of
promastigotes and fluorescence AUF of mCherry. R2, correlation coefficient. Results represent the average of three independent experiments.
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(518ex/605em) daily for 4 days and subsequently plotted against
parasite concentration (Fig. 1D). The background fluorescence
was subtracted from the fluorescence of each sample. Results
demonstrated that the two strains presented a linear relationship
between promastigote number (parasites/ml) and the quantified
fluorescence (arbitrary units of fluorescence [AUF]), with corre-
lation coefficients of0.99.While the linear response for L. major
was between 5 105 and 3 107 parasites/ml,L. donovani showed
a wider range, between 5 105 and 6 107 parasites/ml.
The antileishmanial effects of the reference compounds milte-
fosine (Sigma), amphotericin B (Sigma), and isethionate pentam-
idine (Sigma) were evaluated in transfected parasites and com-
pared with those inWT cultures. The 50% effective concentration
(EC50) was defined as the concentration of drug required to re-
duce by 50% the initial parasite concentration. Culture viability
was assessed by using the fluorometric resazurin-based reference
method CellTiter-Blue (Promega) (25, 26). Briefly, 1  106
cells/ml were seeded in a 96-well plate and incubated in the pres-
ence of increasing drug concentrations for 72 h at 27°C along with
appropriate solvent controls. Afterwards, 20 l of CellTiter-Blue
reagent was added to 100 l of culture. After 4 h at 37°C, fluores-
cence was measured (555ex/580em) using a Typhoon FLA 9500
laser scanner (GE Healthcare) and analyzed with ImageQuant TL
software (GE Healthcare). Table 1 shows the EC50s obtained. For
the three compounds tested, no differences in antileishmanial ac-
tivities were detected, indicating that transfection and constitutive
mCherry expression did not affect drug efficacy. Finally, we eval-
uated the use of mCherry fluorescence quantification in order to
assess cell viability in transgenic Leishmania promastigotes. Lm-
Cherry and LdCherry cultures (1 106 cells/ml, 200 l/well in a
96-well plate) were incubated in the presence of increasing drug
concentrations. After the incubation period (72 h at 27°C), fluo-
rescencewas quantified (518ex/605em) and EC50s were determined
(Table 1). Data reported here show good accordance between
EC50s obtained with the resazurin-based method and by direct
measurement of fluorescent cultures.
To our knowledge, this is the first report in which mCherry-
transfected L. donovani promastigotes were used as a tool to per-
form primary drug screenings. Previous work using Leishmania
major (21) and Leishmania infantum chagasi (22) introduced the
use of mCherry as a reporter gene to monitor in vitro and in vivo
infections. The aim of this work is to validate an alternative
method for primary drug screening on promastigotes of different
Leishmania species. The proposed approach is inexpensive and
does not require the use of host cell-based assays or animal mod-
els. Our results confirm that this approach is rapid and reliable
and is in good accordance with results obtained by the standard
resazurin-based assay. Although the procyclic promastigote form
is not the infective stage and differences in susceptibility to drugs
have been previously addressed, the implementation of a low-cost
methodwith fewmanipulation steps is highly valuable in reducing
the extent of drug libraries. Remarkably, this method requires
only a microplate reader in order to be implemented and can be
easily adapted to automatic drug testing, allowing primary high-
throughput screenings without the need for expensive and sophis-
ticated instruments. This last feature is particularly appealing to
laboratories with limited resources.
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